Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
YUM70
Catalog No.: PC0042
Description: YUM70 is a potent and selective glucose-regulated protein 78 (GRP78) inhibitor with an IC50 of 1.5 μM for inhibiting the ATPase activity of the full-length protein GRP78. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer. YUM70 also has in vivo efficacy in pancreatic cancer xenograft models.
KRAS inhibitor-10
Catalog No.: PC0043
Description: KRAS inhibitor 10 selectively and effectively inhibits RAS proteins, specifically KRAS protein. KRAS inhibitor-10 is an orally active anti-cancer drug that can be used in cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound.
FTO-IN-7
Catalog No.: PC0044
Description: FTO-IN-7 is an inhibitor of FTO. FTO-IN-7 can be used to study Alzheimer's disease, breast cancer, small cell lung cancer, human bone marrow rhabdomyosarcoma, pancreatic cancer, and malignant glioblastoma.
SHP2-IN-22
Catalog No.: PC0045
Description: SHP2-IN-22 is an allosteric inhibitor of SHP2 with an IC50 value of 17.7 nM. SHP2-IN-22 inhibits proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 is useful in Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research.
DX3-234
Catalog No.: PC0046
Description: DX3-234 is an oxidative phosphorylation (OXPHOS) inhibitor. DX3-234 shows significant tumor suppression in the Pan02 syngeneic model of pancreatic cancer.
Nek2-IN-4
Catalog No.: PC0047
Description: Nek2-IN-4 is a potent NEK2 inhibitor with an IC50 of 15 nM. Nek2-IN-4 inhibits cell proliferation. Nek2-IN-4 has potential for pancreatic cancer research.
JI130
Catalog No.: PC0048
Description: JI130 (JI051 derivative) is a stabilizer for the Hes1-PHB2 interaction. JI130 inhibits the ability of Hes1 to repress transcription. JI130 significantly reduces the tumor growth in a murine pancreatic tumor model and has the potential for ?managing pancreatic cancer.
hGAPDH-IN-1
Catalog No.: PC0049
Description: hGAPDH-IN-1, a 3-bromo-4,5-dihydroisoxazole derivative, is a specific and potent covalent inhibitor of hGAPDH. hGAPDH-IN-1 reduces cancer cell growth in different pancreatic cancer cell lines.
KP372-1
Catalog No.: PC0050
Description: KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer).
CM03
Catalog No.: PC0051
Description: CM03 is a potent ligand for DNA G-quadruplexes (G4s). CM03 stabilizes G4, downregulates more G4-containing genes, and increases the incidence of double-strand break events (DSBs) due to torsional strains on DNA and chromatin structures. CM03 has selective potency against pancreatic cancer cells.
Axl-IN-7
Catalog No.: PC0052
Description: Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used to study Axl-related diseases, such as cancer (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma), kidney disease, immune system disease and cardiovascular disease.
KRAS G12C inhibitor 61
Catalog No.: PC0053
Description: KRAS G12C inhibitor 61 inhibits phosphorylated ERK 1/2 in MIA PaCa-2 cells with an IC50 of 9 nM. KRAS G12C inhibitor 61 may be used in studies of pancreatic, colorectal, and lung cancers.
ICy-OH
Catalog No.: PC0054
Description: ICy-OH is an iodinated photosensitizer and an effective anticancer agent. ICy-OH can not only be used for deep tissue imaging (λex=640 nm, λem=690-740 nm), but also selectively induce pancreatic cancer cell death through the pyroptosis pathway.
Bis-Pro-5FU
Catalog No.: PC0055
Description: Bis-Pro-5FU is a 5-FU precursor that confers oral bioavailability and improves the safety of 5-fluorouracil (5-FU) chemotherapy regimens. 5-FU is an antitumor antimetabolite that is widely used in colorectal and pancreatic cancer research.
Manzamine A
Catalog No.: PC0056
Description: Manzamine A is an orally active β-carboline alkaloid that specifically inhibits GSK-3β and CDK-5 with IC50 of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPase and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activity. Manzamine A also exhibits potent anti-HSV-1 activity.
ICy-Q
Catalog No.: PC0057
Description: ICy-Q is a quinone oxidoreductase 1 (NQO-1) activated near-infrared (NIR) reagent that reacts with NQO-1 to release the reduction product ICy-OH. ICy-OH selectively induces pancreatic cancer cell death through the pyroptosis pathway. ICy-Q can be used as an effective tool for rapid and accurate diagnosis of intraoperative pathological slices.
GSD-11
Catalog No.: PC0058
Description: GSD-11 is a potent and selective anti-austerity agent. GSD-11 inhibits the cell migration and colony formation of PANC-1 cells. GSD-11 inhibits the Akt/mTOR signaling pathway. GSD-11 has the potential for the research of pancreatic cancer.
Patritumab
Catalog No.: PC0059
Description: Patritumab (human anti-ERBB3 recombinant antibody) is a neutralizing monoclonal antibody directed against ERBB3. Patritumab acts synergistically with cetuximab (HY-P9905) to effectively inhibit the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces apoptosis and inhibits the growth of pancreatic, non-small cell lung, and colorectal cancer xenograft tumors.
CMLD-2
Catalog No.: PC0060
Description: CMLD-2, an inhibitor of HuR-ARE interaction, competitively binds HuR protein disrupting its interaction with adenine-uridine rich elements (ARE)-containing mRNAs (Ki=350 nM). CMLD-2 induces apoptosis exhibits antitumor activity in different cancer cells as colon, pancreatic, thyroid and lung cancer cell lines. Hu antigen R (HuR) is an RNA binding protein, can regulate target mRNAs stability and translation.
Manzamine A hydrochloride
Catalog No.: PC0061
Description: Manzamine A hydrochloride is an orally active β-carboline alkaloid that specifically inhibits GSK-3β and CDK-5 with IC50 of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPase and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activity. Manzamine A hydrochloride also exhibits potent anti-HSV-1 activity.